Sunteți pe pagina 1din 17

5.

0 Sessions of Interest
High
Medium

Low
Other

Ranking
Programs related to Patiromer, ZS-9, and highly-relevant hyperkalemia
topics
Programs related to hyperkalemia, the RAASi system, RAASi and
LCZ696, and relevant diseases including HF,HTN, or CKD with possible
link to hyperkalemia including treatment options, complications,
outcomes
Programs on pathophysiology of relevant diseases (HTN, HF, CKD),
RAASi or RAAS system with no clear link to potassium or disease
outcomes
Programs on biomarkers, healthcare economics, clinical trials,
publications or technology related to HF and/or CKD

Wednesday, November 16
Session Title

Time

Diagnosis and
Management of
Disorders of Acid-Base,
Fluid, and Electrolyte
Balance: Challenging
Issues for the Clinician

7:30am
6:00pm

Speakers
Treatment of Dyskalemias; Questions and Answers
01:00 PM - 02:00 PM
Thomas D. DuBose, MD, FASN, Winston-Salem, NC
Selection of Fluid Therapy in Patients with Medical or
Surgical Conditions; Questions and Answers
02:00 PM - 03:00 PM
Biff F. Palmer, MD, FASN, Dallas, TX
Break
03:00 PM - 03:30 PM
Treatment of Acute Disorders of Magnesium,
Calcium, and Phosphorus Balance; Questions and
Answers
03:30 PM - 04:30 PM
David A. Bushinsky, MD, Rochester, NY
Illustrative Cases
04:30 PM - 05:30 PM
David A. Bushinsky, MD, Rochester, NY
Thomas D. DuBose, MD, FASN, Winston-Salem, NC
Biff F. Palmer, MD, FASN, Dallas, TX
Questions and Answers
05:30 PM - 06:00 PM
David A. Bushinsky, MD, Rochester, NY

Thomas D. DuBose, MD, FASN, Winston-Salem, NC


Biff F. Palmer, MD, FASN, Dallas, TX

Thursday, November 17
Session
Title
Opening
Plenary:
President's
Address,
Former
Councilors
Recognition,
ASN/ERAEDTA/ISN
Declaration of
Collaboration,
State-of-the-Art
Lecture

Giving and
Receiving: Role
of the Physician
in Patient
Transitions of
Care, Including
the Christopher
R. Blagg, MD,
Lectureship in
Renal Disease
and Public
Policy

Time

Locatio
n

Speakers
President's Address
08:00 AM - 08:30 AM
Raymond C. Harris, MD, FASN, Nashville, TN
Former Councilors Recognition
08:30 AM - 08:45 AM

8:009:30am

W375C-E

ASN/ERA-EDTA/ISN Declaration of
Collaboration
08:45 AM - 08:50 AM
State-of-the-Art Lecture "The Causes and
Consequences of Human Obesity: Lessons
from Genetics
08:50 AM - 09:30 AM
Stephen O'Rahilly, MD, Cambridge, United
Kingdom
Chairs:
Rebecca J. Schmidt, DO, FASN, Morgantown,
WV
Suzanne Watnick, MD, Portland, OR
Optimizing Transitions for our Patients in and
out of the Hospital
10:30-11:00am
David Meltzer MD, PhD, Chicago, IL

10:3012:30pm

W179

Facilitating Transitions on and off Dialysis


11:00-11:30am
Raymond M. Hakim, MD, PhD, Portland,
Oregon
Transplant Transitions: How Do We Prepare for
a Kidney Allograft and its Subsequent Loss?
11:30-12:00pm
Roy D. Bloom, MD, Philadelphia, PA
Implementation and Impact of Transitional
Clinics for Pediatric CKD Patients
12:00-12:30pm
Mina Matsuda-Abedini, MD, San Francisco, CA

Chair:
Sharon G. Adler, MD, FASN, Los Angeles, CA

Prevention and
Treatment of
Chronic
Hyperkalemia

Introduction
12:45-12:55pm
Sharon G. Adler, MD, FASN, Los Angeles, CA

12:451:45pm

S100A

**Supported by
Relypsa

Epidemiology of Hyperkalemia: Who is at


Risk?
12:55-1:15pm
Stephen L. Seliger, MD, Baltimore, MD

Approaches to Prevent and Treat Chronic


Hyperkalemia
1:15-1:35pm
Csaba P. Kovesdy, MD, Memphis, TN
Chair:
Sadiq Ahmed, MD, Lexington, KY
Introduction
12:45-12:55pm
Sadiq Ahmed, MD, Lexington, KY

A Balanced
Approach to
Phosphorus
Balance

CKD-MBD
Guideline
Update: A
Critical
Appraisal of
Recent Studies

12:451:45pm

Regency
Ballroom

Reasonable Diet in CKD and ESRD: What to


Eat and How 12:55-1:15pm
Adamasco Cupisti, MD, PhD, Pisa, Italy
Relative Roles of Diet and Binders in the
Control of Phosphorus
1:15-1:35pm
Kamyar Kalantar, Zadeh, MD, PhD, FASN,MPH

12:451:45pm

W196

Questions and Answers


1:35-1:45pm
Chair:
Tamara Isakova, MD, Chicago, IL
Introduction
12:45-12:55
Tamara Isakova, MD, Chicago, IL
Vascular Calcification, Calcium and Phosphate
in CKD Patients Not yet on Dialysis
12:55-1:15pm
Markus Ketteler, MD, Rhede, Germany
PTH, Vitamin D and Bone Health in CKD
Patients Not yet on Dialysis
1:15-1:35pm Sharon M. Moe, MD, FASN,

Indianapolis, IN
Questions and Answers
1:35-1:45pm
Chairs:
Yong-Lim Kim, MD, Ph D, Jung-gu, Daegu
Peter Margetts, MD, PhD, Hamilton, Ontario,
Canada
Advances in Understanding of Peritoneal
Fibrosis
2:00-2:30pm
Shuei-Liong Lin, MD, PhD, Taipei, Taiwan

Peritoneal
Dialysis and a
Scarred Belly

2:004:00pm

W184

Pathophysiology of Changes in Salt and Water


Removal with Long-Term PD
2:30-3:00pm
Olivier Devuyst, MD, PhD, Zurich, Switzerland

Dialysate Composition and Long-Term


Changes in Peritoneal Function
3:00-3:30pm
Isaac Teitelbaum, MD, Aurora, CO

You Are What


You Eat: Diet
and CKD

2:004:00pm

W185

Predicting Individual Risk for Encapsulating


Peritoneal Sclerosis
3:30-4:00pm
Edwina A. Brown, MD, London, UK
Chairs:
Talat Alp Ikizler, MD, FASN, Nashville TN
Anna Jeanette Jovanovich, MD, Denver, CO

Is the Health of the General Population at Risk


Due to High Phosphorus Intake?
2:00-2:30pm
Jaime Uribarri, MD, New York, NY
What is the Current Status of Phosphorus
Content on Food Labels?
2:30-3:00pm
Mona S. Calvo, MS, PhD, Laurel, MD
Dietary Potassium Intake and CKD
Progression: Friend or Foe?
3:00-3:30pm
Sharon Turban, MD, Baltimore, MD
Eat Your Fruits and Vegetables: Dietary Acid

Load and CKD


3:30-4:00pm
Donald E. Wesson, MD, FASN, Temple, TX
Chairs:
Michael J. Choi, MD, Baltimore, MD
Mark A. Perazella, MD, FASN, New Haven, CT
Electrolyte and Acid-Base Disturbances
2:00-2:30pm
Mitchell H. Rosner, MD, FASN, Charlottesville,
VA

Nephrology
Quiz and
Questionnaire

2:004:00pm

W375B

Glomerular Diseases
2:30-3:00pm Andrew S. Bomback, MD, MPH,
New York, NY
Transplantation
3:00-3:30pm Margaret J. Bia, MD, New Haven,
CT
Renal Replacement Therapy
3:30-4:00pm
Charmaine E. Lok, MD, MPH, Toronto, Ontario,
Canada
Chairs:
Michael Allon, MD, Birmingham, Alabama
Jerry Yee, MD, FASN, Detroit, Michigan
Beyond the Guidelines: Patient Irrelevance?
2:00-2:30pm
Louis M. Moist, MD, London, Canada

Discompuzzled:
What to Do
When Practice
and Evidence
Don't Align

Making
Nephrology an
On-Study

2:004:00pm

S102

Here's the Key Evidence That We Dont


Follow
2:30-3:00pm
Anthony J. Bleyer, MD, FASN, Winston Salem,
NC
Practices that Actually Work to Improve
Dialysis and Outcomes for Patients
3:00-3:30pm
Daniel E. Weiner, MD, FASN, Boston, MA

2:004:00pm

W183C

Truths and Tricks: What Really Happens in the


Dialysis Unity
3:30-4:00pm
Joanne M. Bargman, MD, Toronto, ON
Chairs:
Matthew D. Breyer, MD, FASN, Indianapolis, IN

Kimberly A. Smith, MD, MS, Columbia,


Maryland
Where Are All the Patients? Physician and
Patient Barriers to Clinical Trial Recruitment
2:00-2:30pm
Katherine R. Tuttle, MD, FASN, Spokane, WA

Developing the Right Biomarker: From


Pathogenesis to Surrogate End Point
2:30-3:00pm
John-Michael Sauer, PhD, Tucson, AZ

Specialty:
Challenges and
Opportunities

Optimizing Clinical Trial Design and


Infrastructure
3:00-3:30pm
Jula K. Inrig, MD, MS, FASN, Durham, NC
The New Dialysis Unit: A Factory for
Innovation and Clinical Research
3:30-4:00pm
Prabir Roy-Chaudhury, MD, PhD, FASN,
Tucson, AZ
Chairs:
Michael Chonchol, MD, Denver, CO
Paul E. Drawz, MD, Minneapolis, MN
Intensive Blood Pressure Control and CKD
Progression in SPRINT
2:00-2:30pm
Mahboob Rahman, MD, Cleveland, OH

SPRINTing to
New BP
Treatment
Goals

2:004:00pm

W375A

Intensive Blood Pressure Control and Risk of


AKI in SPRINT
2:30-3:00pm
Michael V. Rocco, MD, Winston-Salem, NC
Intensive Blood Pressure Control and CVD
Events in CKD Patients in SPRINT
3:00-3:30pm
Alfred K. Cheung, MD, Salt Lake City, UT

Clinical and
Translational
Science to

2:004:00pm

W192

Integrating SPRINT Findings with Results of


Prior Blood Pressure Trials in CKD Patients
3:30-4:00pm
Lawrence J. Appel, MD, MPH, Baltimore, MD
Chairs:
Frank C. Brosius, MD, Ann Arbor, MI
Matthias Kretzler, MD, Ann Arbor, MI

Genetic Polymorphisms Predisposing to CKD


in Blacks and Latinos
2:00-2:30pm
Karl Leon Skorecki, MD, FASN, Haifa, Israel

Contributions of Environment and Diet to


Health Disparities
2:30-3:00pm
Orlando M. Gutierrez, MD, Birmingham, AL

Reduce Health
Disparities

Can mHealth Reduce Disparities in Kidney


Care?
3:00-3:30pm
Clarissa Jonas Diamantidis, MD, Durham, NC
Health System Innovations to Reduce
Disparities
3:30-4:00pm
L. Ebony Boulware, MD, MPH, Durham, NC
Chairs:
Friedrich K. Port, MD, Ann Arbor, MI
Raymond C. Vanholder, MD, PhD, Gent,
Belgium

Dialysis
Outcomes and
Practice
Patterns Study
Program:
Celebrating 20
Years and
Looking Ahead

Paradigm Shifts
in Diabetic

Key Hemodialysis Practice Changes and Their


Impact
4:30-5:00pm
Bruce M. Robinson, MD, FASN, MPH, Ann
Arbor, MI

4:306:30pm

W375A

"Ask Your Patients and Do Something About


It": The Patient Experience in DOPPS
5:00-5:30pm
Francesca Tentori, MD, Ann Arbor, MI
CKDopps: Improving Care in Advanced CKD
and the Dialysis Transition Period
5:30-6:00pm
Benedicte Stengel, MD, PhD, Paris, France

4:306:30pm

W375B

PDOPPS: What Can We Learn about PD


through the DOPPS Approach?
6:00-6:30pm
David W. Johnson, DrMed, MBBS, PhD, FASN,
Oak Brook , IL
Chairs:
Ricardo Correa-Rotter, MD, Mexico City,

Mexico

Raimund T.H. Pichler, MD

DKD Diagnosis: Much More than Albuminuria


4:30-5:00pm
Amy K. Mottl, MD, MPH, Chapel Hill, NC
DKD Heterogeneity in Type 1 versus Type 2
Diabetes
5:00-5:30pm
Michael Mauer, MD, Minneapolis, MN
Changing Natural History of Diabetic
Complications in Type 1 Diabetes
5:30-6:00pm
Per-Henrik Groop, MD, PhD, Helsinki, Finland

Kidney Disease

DKD Risks DKD : Death, Cardiovascular


Disease, and Infections
6:00-6:30pm
Maryam Afkarian, MD, PhD, Seattle, WA
Chairs:
Frank P. Hurst, MD, FASN, Silver Spring, MD
Prabir Roy-Chaudhury, MD, PhD, FASN,
Tucson, AZ
Developing Therapies that Make a Difference:
Why the Patient Voice Matters
4:30-5:00pm
Kevin John Fowler, Chicago, IL

Patient-Centric
Approaches to
Kidney Disease
Innovation

4:306:30pm

W184

Using Patient Portals to Facilitate Drug and


Device Development
5:00-5:30pm
Lauren Lee, Philadelphia, PA
Incorporating Patient Perspectives to Develop
Patient-Centric Therapies
5:30-6:00pm
Ronald D. Perrone, MD, FASN, Boston, MA
FDA-Patient Partnerships : Moving the Needle
6:00-6:30pm
Anindita Saha, Silver Spring, MD

CKD and AKI


Clinical Trials
The Lifeline of
Hemodialysis
Diet in CKD and
ESRD: Does it
Really Matter?

4:306:30pm
4:306:30pm
4:306:30pm

S103
W187
W183A

Biomarkers and
Treatments of
CKD
CKD: Mental
Health, Quality
of Life, Health
Services,
Disparities

4:306:30pm

W179

4:306:30pm

W183B

Friday, November 18
Session
Title
Plenary: ASN
Foundation for
Kidney
Research
Recognition,
Diamond Level
Corporate
Supporters
Recognition,
Former Award
Recipients,
Recognition,
State of the Art
Lecture
What Do the
Large
Nephrology
Databases Tell
Us?
Implications for
Future Kidney
Care

Time

Locatio
n

Speakers
ASN Foundation for Kidney Research
Announcement
8:00-8:10am

8:009:30am

Diamond Level Corporate Supporters


Recognition
8:10-8:15am

W375C-E
Former Award Recipients Recognition
8:15-8:45am
State-of-the-Art Lecture "Reflex Circuits in
Immunity: Bioelectronic Medicine"
8:45-9:25am
Kevin J. Tracey, MD, Manhasset, NY

10:3012:30pm

W178

Chairs:
Kevin F. Erickson, MD, MS, Houston, TX
Wolfgang C. Winkelmayer, MD, PhD, MPH,
Houston, TX
DOPPS: Recent Findings and Implications for
the Future of Kidney Care Delivery
10:30-11:00am
Francesca Tentori, MD, Ann Arbor, MI
PEER: Recent Findings and Implications for the
Future of Kidney Care Delivery
11:00-11:30am
Allan J. Collins, MD, Minneapolis, MN
USRDS: Recent Findings and Implications for
the Future of Kidney Care Delivery
11:30-12:00pm

Richard A. Hirth, PhD, Ann Arbor, MI


Promoting Infection Prevention in Dialysis
Facilities Project
12:00-12:30pm
Alan S. Kliger, MD, New Haven, CT
Chairs:
Aaron J. Polichnowski, PhD, Hines, IL
Johannes Stegbauer, MD, Duesseldorf,
Germany

Getting on Your
Nerves: Role of
Sympathetic
and
Parasympatheti
c Outflow in
Hypertension
and CKD

Renal Denervation Limits Kidney Fibrogenesis


10:30-11:00am
Babu J. Padanilam, PhD, Omaha, NE

10:3012:30pm

W190A

Renal-Cerebral Reflex Promotes CKD


Progression
11:00-11:30am
Fan Fan Hou, MD, PhD, GuangZhou, China
Superoxide in the CNS: Radical View of
Hypertension
11:30-12:00pm
Matthew Zimmerman, PhD, Omaha, NE
Neuroimmune Interactions Contribute to
Hypertension
12:00-12:30pm
Daniela Carnevale, PhD, Rome, Italy
Chairs:
Charmaine E. Lok, MD, MPH, Toronto, Ontario,
Canada
Bessie A. Young, MD, MPH,
FASN, Seattle, WA

Home
Hemodialysis:
Alpha to Omega

Biomarker
Identification
and Validation
in the

10:3012:30pm

10:3012:30pm

HHD: Infrastructure, Water, and Machines


John W. MacD, Agar, MBBS, Geelong, Australia

W375B

W192

HHD: Patient Selection and Maintaining


Vascular Access Robert S. Lockridge, MD,
Lynchburg, Virginia
HHD: Prescription, Adequacy, and
Complications Andreas Pierratos, MD, Toronto,
ONHHD: Outcome Studies Christopher T.
Chan, MD, Toronto, ON
Chairs:
Sharon G. Adler, MD, FASN, Los Angeles, CA
Rulan S. Parekh, MD, MS, FASN, Toronto, ON

Guidelines for Identification and Validation of


Biomarkers in CKD
10:30-11:00am
Jon B. Klein, MD, PhD, Louisville, KY
Biomarkers of Structural Pathology in Diabetic
Kidney Disease and Renal Function Decline The Robert W. Schrier, MD, Endowed
Lectureship
11:00-11:30am
Robert G. Nelson, MD, PhD, Bethesda, MD

Management of
CKD, Including
the Robert W.
Schrier, MD,
Endowed
Lectureship

Novel Biomarkers for Diabetic Nephropathy in


Type 1 Diabetes
11:30-12:00pm
Janet Snell-Bergeon, PhD, Denver, CO
Biomarkers to Predict Progression to ESRD
12:00-12:30pm
Steven G. Coca, DO, New York, NY
Chair:
Jay B. Wish, MD, Indianapolis, IN

Expanding the
Therapeutic
Armamentariu
m for Treatment
of Anemia of
Kidney Disease

KDIGO
Guidelines in
CKD-Mineral
and Bone
Disorder: Time
for
Reassessment?

Introduction: Unmet Needs in the Treatment


of Anemia of Kidney Diseases
12:45-12:55pm
Jay B. Wish, MD, Indianapolis, IN

12:451:45pm

S100A

HIF Biology and Anemia of Kidney Diseases


12:55-1:15pm
Mark Koury, MD, Nashville, TN
Development and Early Clinical Experience
with HIF Activators
1:15-1:35pm
Abhijit V. Kshirsagar, MD, MPH, Chapel Hill, NC

12:451:45pm

Regency
Ballroom

Questions and Answers


1:35-1:45pm
Chair:
Marcello Tonelli, MD, Alberta, Canada
Introduction
12:45-12:55pm
Marcello Tonelli, MD, Alberta, Canada
Phosphate: What's New in the Guideline?
12:55-1:15pm
David C. Wheeler, MD, London, UK

What Should We Use for the Management of


Secondary Hyperparathyroidism: Vitamin D
Analogues or Calcimimetics?
1:15pm-1:35pm
Ravi I. Thadhani, MD, MPH, Boston, MA
Questions and Answers
1:35-1:45pm
Chair:
Areef Ishani, MD, Minneapolis, MN

Fluid
Management in
Hemodialysis:
Determining
the Goal and
Reaching It

Introduction
12:45-12:55pm
Areef Ishani, MD, Minneapolis, MN

12:451:45pm

S100B-C

New Methods in Assessing Dry Weight


12:55-1:15pm
Steven M. Brunelli, MD, Minneapolis, MN
Target Weight and Ultrafiltration Rate:
Optimate Approach to Fluid Management
1:15-1:35pm
Jennifer E. Flythe, MD, FASN, MPH, Chapel Hill,
NC
Questions and Answers
1:35-1:45pm
Chair:
Linda F. Fried, MD, FASN, MPH, Pittsburgh, PA

Approach to the
Management of
Acute and
Chronic
Hyperkalemia
in the
Complicated
Patient

Introduction
12:45-12:55pm
Linda F. Fried, MD, FASN, MPH, Pittsburgh, PA

12:451:45pm

S401

New and Old Approaches to Management: A


Case-Based Approach
1:15-1:35pm
James A. Tumlin, MD, FASN, Chattanooga, TN

**Supported by
ZS

Highlights from

Physiology and Treatment of Acute


Hyperkalemia
12:55-1:15pm
Biff F. Palmer, MD, FASN, Dallas, TX

2:00-

S103

Questions and Answers


1:35-1:45pm
Chairs:

Denis Fouque, MD, PhD, Lyon, France


Andrzej Wiecek, MD, PhD, Katowice, Poland

ERA-EDTA
Congress in
Vienna

Transplantation
2:00-2:30pm
Rainer Oberbauer, MD, FASN, Vienna, Austria
CKD/Nutrition
2:30-3:00pm
Denis Fouque, MD, PhD, Lyon, France

4:00pm

Dialysis
3:00-3:30pm
Peter J. Blankestijn, MD, FASN, Groningen,
Netherlands
Glomerulonephritis/Immunology
3:30-4:00pm
David R.W. Jayne, MD, Cambridge, UK
Chairs:
L. Ebony Boulware, MD, MPH, Durham, NC
Leslie P. Wong, MD, FASN, Cleveland, OH

Telemedicine 101: Goals, Use, Legislation,


Regulation
2:00-2:30pm
Robert Jarrin, Washington DC

iPatient:
Providing
Kidney Care via
Telehealth

2:004:00pm

W190B

VA Experience with Telemedicine in a Large,


Integrated Health Care System
2:30-3:00pm
Areef Ishani, MD, Minneapolis, MN
Home Dialysis and the Future of Remote
Patient Monitoring in Nephrology
3:00-3:30pm
Susie Q. Lew, MD , FASN, Washington, DC

Marching
Forward with
New Treatments
for Old Ailments

2:004:00pm

W185

Benefits of HIT for Population Management in


CKD
3:30-4:00pm
Uptal D. Patel, MD, Durham, NC
Chairs:
Michel Chonchol, MD, Denver, CO
Paul L. Kimmel, MD, Washington, DC

HIF Prolyl Hydroxylase Inhibitors and Anemia


of ESRD
2:00-2:30pm

Jeffrey S. Berns, MD, FASN, Philadelphia, PA

Drug Dialyzability and Antihypertensive Drug


Selection
2:30-3:00pm
Amit X. Garg, MD, PhD, London, ON
Mineralocorticoid Receptor Antagonists for
Dialysis Patients: Safe and Effective?
3:00-3:30pm
David M. Charytan, MD, Boston, MA

Feeling the
Pinch of Salt:
Intrarenal
ReninAngiotensin
System and
Hypertension

Management of
Diabetes in
Diabetic Kidney
Disease: Are
We Doing It
Right?

2:004:00pm

2:004:00pm

S105

W179

Na-Pi and NHE3 Inhibitors for Management of


Hyperphosphatemia of ESRD
3:30-4:00pm
Tamara Isakova, MD, Chicago, IL
Chairs: Thu H. Le, MD, Charlottesville, VA
Tianxin Yang, PhD, Salt Lake City, UT
Role of Collecting Duct Renin in the
Pathogenesis of Hypertension 2:002:30pmMinolfa C. Prieto, MD, PhD, New
Orleans, LA
Key Interactions between the
Dopaminergic and Renin Angiotensin Systems
in Hypertension2:30-3:00pm Pedro A. Jose,
MD, PhD, Washington, DC
Blood Pressure
Regulation by the Type 1 Angiotension
Receptor in the Proximal Tubule3:00-3:30pm
Susan B. Gurley , MD, PhD, Durham, NC
Intrarenal ACE as a Catalyst for Hypertension
3:30-4:00pmRomer Andres GonzalezVillalobos, MD, PhD, Cambridge, MA
Chairs:
Vlado Perkovic, MBBS, FASN, Sydney,
Australia
Peter Rossing, MD, Gentofte, Denmark
How and Why to Monitor Diabetes in CKD and
ESRD
2:00-2:30pm
Mark E. Molitch, MD, Chicago, IL
Upcoming New Targets for DKD
2:30-3:00pm
Rajiv Agarwal, MBBS, MD, FASN, Indianapolis,
IN
DKD: Are SGLT2 Inhibitors the Solution?
3:00-3:30pm
David Cherney, MD, PhD, Toronto, ON

Gut-Renal Axis: Do Incretin-Based Agents


Confer Renoprotection in Diabetes?
3:30-4:00pm
Marcel H.A. Muskiet, MD, Amsterdam,
Netherlands
Chairs:
James A. Shayman, MD, FASN, Ann Arbor, MI
Eric E. Simon, MD, New Orleans, LA

PhysiologyBased
Approach to
Management of
Common
Electrolyte
Disorders

Hypertension
Challenges
across the
Spectrum of
CKD

Bridging the
Gap between
Evidence and
Practice of
Peritoneal
Dialysis

Hyponatremia
2:00-2:30pm
Tomas Berl, MD, FASN. Denver, CO

2:004:00pm

S102

Hyperkalemia
2:30-3:00pm
Csaba P. Kovesdy, MD, Memphis, TN
Diabetic Ketoacidosis
3:00-3:30pm
Mitchell L. Halperin, MD, Toronto, ON

4:306:30pm

4:306:30pm

W375B

W375A

Hypercalcemia
3:30-4:00pm
R. Tyler Miller, MD, Dallas, TX
Chairs: Debbie L. Cohen, MD, Philadelphia, PA
Abhijit V. Kshirsagar, MD, MPH, Chapel Hill, NC
Dont Let Me Down: Re-Evaluating Blood
Pressure Goals for Treated Hypertension in
CKD4:30-5:00pm Csaba P. Kovesdy, MD,
Memphis, TNTo ARB or Not to ACE-I: Which
Agent Should Be the First for Treating
Hypertension in CKD?5:00-5:30pm Sankar D.
Navaneethan, MD, MS, FASN, MPH, Cleveland,
OH
Hypertension in Dialysis: Is it All Salt
and Water?5:30-6:00pm Jennifer E. Flythe,
MD, FASN, MPH, Chapel Hill, NC
Hypertension in Kidney Transplantation6:006:30pm Sarah L. Elfering, MD, Minneapolis,
MN
Chairs:
Mark Lambie, MBChB, PhD, Staffordshire, UK
Roberto Pecoits-Filho, MD, PhD, FASN,
Curitiba, Paran, Brazil
PD Survival in the First Year and a Targeted
Approach to Prolong Time on Therapy
4:30-5:00pm

Arsh Jain, MD, London, ON


Peritonitis: How to Bridge the Gap between
Evidence and Practice
5:00-5:30pm
David W. Johnson, DrMed, MBBS, PhD, FASN,
Oak Brook , IL
Evidence-Based Approach for Volume
Management of PD Patients
5:30-6:00pm
Simon J. Davies, MD, Staffordshire, UK

Sodium on the
Podium: The
Kidney in
Hypertension
PatientCentered
Outcomes with
Maintenance
Dialysis
GFR Estimation
and CKD
Epidemiology
for NonCardiovascular
End Points

Hyponatremia in PD: More than Just a Lab Test


6:00-6:30pm
Connie Rhee, MD, Orange, CA
Chairs:
Jennifer M. Sasser, PhD, Jackson, MS
Andrey Sorokin, PhD, Milwaukee, WI

4:306:30pm

W190B

4:306:30pm

W185

4:306:30pm

W179

Renal Effects of a Fructose-Enriched Diet:


Interaction with High Salt Intake
5:54pm-6:30pm
Pablo A. Ortiz, PhD, Detroit, MI